Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 42, 2010, Pages 17933-17938

  Yuen, William W ^a   Du, Nan R ^a   Chan, Chun H ^b   Silva, Eduardo A ^a   Mooney, David J ^a  

^a HARVARD UNIVERSITY   (United States)

^b Cornell University   (United States)

Author keywords

Controlled drug delivery; Diffusion reaction; Peripheral ischemia; Turing pattern; VEGF antibody

Indexed keywords

POLYMER; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIMB ISCHEMIA; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, SCID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149259034     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001192107     Document Type: Article

References (43)

1. Richardson TP, et al. (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19:1029-1034. (Pubitemid 33041886)
2. Bonauer A, et al. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:1710-1713.
3. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395.
4. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18.
5. Yancopoulos GD, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
6. Takeshita S, et al. (1994) Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93:662-670.
7. Henry TD, et al. (2003) The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107:1359-1365.
8. Dor Y, Djonov V, Keshet E (2003) Making vascular networks in the adult: Branching morphogenesis without a roadmap. Trends Cell Biol 13:131-136. (Pubitemid 36293785)
9. Noguera-Troise I, et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032-1037. (Pubitemid 46018516)
10. Thurston G, Noguera-Troise I, Yancopoulos GD (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7:327-331. (Pubitemid 46652486)
11. Silva EA, Mooney DJ (2007) Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5:590-598.
12. Barrio RA, et al. (1999) A two-dimensional numerical study of spatial pattern formation in interacting Turing systems. Bull Math Biol 61:483-505.
13. Faissner A, Steindler D (1995) Boundaries and inhibitory molecules in developing neural tissues. Glia 13:233-254.
14. Turing AM (1952) The chemical basis of morphogenesis. Philos Trans R Soc London B 237:37-72.
15. Turing AM (1990) The chemical basis of morphogenesis. 1953. Bull Math Biol 52: 153-197 discussion pp 119-152.
16. Fleming AB, Saltzman WM (2001) Simultaneous delivery of an active protein and neutralizing antibody: Creation of separated regions of biological activity. J Control Release 70:29-36.
17. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974.
18. Sun Q, et al. (2005) Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res 22:1110-1116. (Pubitemid 41127068)
19. Harris LD, Kim BS, Mooney DJ (1998) Open pore biodegradable matrices formed with gas foaming. J Biomed Mater Res 42:396-402.
20. Chen RR, et al. (2007) Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 24:258-264.
21. Helm CLE, et al. (2005) Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc Natl Acad Sci USA 102:15779-15784.
22. Brouwers JEM, et al. (2006) Can the growth factors PTHrP, Ihh and VEGF, together regulate the development of a long bone? J Biomech 39:2774-2782.
23. Clauss MA, Jain RK (1990) Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res 50:3487-3492.
24. Pluen A, et al. (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 98:4628-4633.
25. Crank J (1975) The Mathematics of Diffusion, (Clarendon, Oxford, England), 2d Ed, viii, p 414.
26. Vieira P, Rajewsky K (1988) The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 18:313-316.
27. Vieira P, Rajewsky K (1986) The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL/6 mice with a half-life of 6-8 days. Eur J Immunol 16:871-874.
28. Presta LG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599.
29. Chen RR, et al. (2007) Integrated approach to designing growth factor delivery systems. FASEB J 21:3896-3903.
30. Wang Y, et al. (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335-345. (Pubitemid 40767935)
31. Ozawa CR, et al. (2004) Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113:516-527.
32. Sheridan MH, et al. (2000) Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release 64:91-102.
33. Jain RA (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490.
34. Ridgway J, et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083-1087.
35. Sick S, et al. (2006) WNT and DKK determine hair follicle spacing through a reactiondiffusion mechanism. Science 314:1447-1450. (Pubitemid 44871949)
36. Kondo S, Asai R (1995) A reaction-diffusion wave on the skin of the marine angelfish Pomacanthus. Nature 376:765-768.
37. Jiang TX, et al. (1999) Self-organization of periodic patterns by dissociated feather mesenchymal cells and the regulation of size, number and spacing of primordia. Development 126:4997-5009.
38. Eldar A, Shilo BZ, Barkai N (2004) Elucidating mechanisms underlying robustness of morphogen gradients. Curr Opin Genet Dev 14:435-439.
39. Eldar A, et al. (2003) Self-enhanced ligand degradation underlies robustness of morphogen gradients. Dev Cell 5:635-646.
40. Eldar A, et al. (2002) Robustness of the BMP morphogen gradient in Drosophila embryonic patterning. Nature 419:304-308.
41. von Dassow G, et al. (2000) The segment polarity network is a robust development module. Nature 406:188-192.
42. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
43. Richards Grayson AC, et al. (2003) Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2:767-772.